RAMP Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy
- Coordinator
- Institut National De La Sante Et De La Recherche Medicale, France
- Runs
- 1 September 2026 to 31 August 2031
- Status
- Running
- EU funding
- €10.3m
- Total cost
- €13.9m
- Partners
- 12 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101248869
What the project is doing
In the project's own words, from its summary on CORDIS.
In the context of growing parasite resistance to drugs in malaria, new agents are needed to regain control on this deadly infection affecting mainly children. By a large screen, we uncovered that ravidasvir, licensed by the Egyptian company Pharco and approved with support from DNDi as part of an affordable cure for hepatitis C, is active against asexual and sexual stages of Plasmodium falciparum. In the framework of this EDCTP3 program, we aim to clinically validate the ability of ravidasvir to clear parasites thereby preventing disease resurgence and blocking transmission.
The Ravidasvir Against Malaria Parasites (RAMP) project has 3 objectives: assess the efficacy of ravidasvir at reducing parasite carriage and block transmission to Anopheles, assess the ability of ravidasvir to complement Artemisinin-based Combination Therapies (ACT) to sustainably cure patients, and assess perception and compliance of anti-transmission drugs/drug combinations across different countries to inform elimination programs.
Drug safety, possible drug-drug interactions and resistance markers will be scrutinized. Our strong, synergistic African - European consortium will initially test ravidasvir as a monotherapy in asymptomatic adults carrying gametocytes in Gabon. We will then evaluate ravidasvir co-administered with a WHO-recommended ACT in adults with uncomplicated malaria attacks in Mali. We will finally perform a non-inferiority Phase 3 trial in Ghana, Gabon, Mali and Uganda, with age de-escalation to rapidly but safely reach African children where artemisinin resistance will be or is already present.
RAMP can rapidly repurpose ravidasvir for malaria, based on its promising, physiologically relevant dual activity in vitro. This cost-effective oral drug, devoid of severe side effects when administered for 12 weeks in hepatitis C, has a very strong potential to be safely co-administered for 3 days with ACT as a protection against parasites resistant to artemisinin and partner drugs.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Coordinator |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| Pharco Pharmaceuticals, Chemicals and Investments (s.a.e.) | Alexandria | Egypt | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Third party |
| Epicentre | Paris | France | Participant |
| Institut De Recherche Pour Le Developpement | Marseille | France | Participant |
| Centre de Recherches Medicales de Lambaréné | Lambaréné | GA | Participant |
| Ghana Health Service | Accra | Ghana | Participant |
| Kwame Nkrumah University of Science and Technology Kumasi | Kumasi | Ghana | Participant |
| Reseau Africaine pour l'Etude de la Diversite Genomique des Pathogens | Bamako | ML | Third party |
| Universite Des Sciences Des Techniques Et Des Technologies De Bamako | Bamako | ML | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI